Physician profile

David Ian Katz

Hand Surgery · Athens, GA

NPI 1407034531

$674.68

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$96.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Axogen $266.59 2019-2020
Stryker Corporation $82.35 2021
Depuy Synthes Sales INC. $78.97 2019-2022
Horizon Therapeutics Plc $63.11 2019-2022
Acumed LLC $60.87 2023 Acumed, Inframe Implant
Bioventus LLC $37.15 2019-2024 Exogen Ultrasound Bone Healing System
Pacira Therapeutics, INC. $31.71 2020-2021
Radius Health, INC. $24.23 2022
Treace Medical Concepts, INC. $15.90 2024
Ferring Pharmaceuticals INC. $13.80 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David Ian Katz

$674.68

in general payments reported 2019-2025

Years
2019-2024
Top company
Axogen

https://glasscript.com/doctor/62871/david-ian-katz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.